Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
26.28
+0.32 (1.23%)
Aug 12, 2026, 12:54 PM EDT - Market open
Nurix Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is December - November.
Millions USD. Fiscal year is Dec - Nov.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Cash & Equivalents | 67.69 | 246.96 | 110 | 54.63 | 64.47 | 80.51 |
Short-Term Investments | 375.84 | 345.98 | 499.59 | 233.28 | 244.67 | 215.21 |
Cash & Short-Term Investments | 443.53 | 592.94 | 609.58 | 287.91 | 309.14 | 295.72 |
Cash Growth | -8.70% | -2.73% | 111.73% | -6.87% | 4.54% | 5.18% |
Accounts Receivable | - | - | - | - | - | 6 |
Other Receivables | - | - | - | - | - | 0.2 |
Total Trade Receivables | - | - | - | - | - | 6.2 |
Other Current Assets | 12.95 | 13.88 | 9.8 | 7.6 | 9.31 | 9.19 |
Total Current Assets | 456.48 | 606.82 | 619.39 | 295.5 | 318.45 | 311.12 |
Net Property, Plant & Equipment | 70.11 | 73.01 | 45.9 | 47.95 | 29.51 | 25.35 |
Long-Term Investments | - | - | - | 7.42 | 63.88 | 137.19 |
Other Long-Term Assets | 8.95 | 8.31 | 4.06 | 4.72 | 4.92 | 3.12 |
Total Assets | 535.54 | 688.14 | 669.34 | 355.6 | 416.76 | 476.77 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Accounts Payable | 12.21 | 11.22 | 11.48 | 6.4 | 5.06 | 6.65 |
Accrued Expenses | 43.27 | 54.85 | 37.99 | 24.97 | 22.43 | 14.55 |
Current Portion of Leases | 3.22 | 2.82 | 8.01 | 7.49 | 5.53 | 3.85 |
Unearned Revenue | 13.32 | 17.58 | 38.36 | 48.1 | 37.63 | 41.21 |
Total Current Liabilities | 72.02 | 86.47 | 95.85 | 86.96 | 70.66 | 66.26 |
Long-Term Leases | 54.92 | 52.91 | 20.29 | 23.13 | 6.43 | 9.19 |
Other Long-Term Liabilities | 5.97 | 10.01 | 26.21 | 45.02 | 35.97 | 59.02 |
Total Long-Term Liabilities | 60.89 | 62.92 | 46.5 | 68.15 | 42.41 | 68.21 |
Total Liabilities | 132.91 | 149.39 | 142.35 | 155.11 | 113.06 | 134.47 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Common Stock | 0.1 | 0.1 | 0.08 | 0.05 | 0.05 | 0.05 |
Additional Paid-in Capital | 1,583 | 1,542 | 1,266 | 746.3 | 709.22 | 563.76 |
Accumulated Other Comprehensive Income | -0.15 | 0.11 | 0.15 | -0.66 | -4.32 | -0.61 |
Retained Earnings | -1,180 | -1,003 | -738.77 | -545.2 | -401.25 | -220.89 |
Shareholders' Equity | 402.63 | 538.75 | 526.99 | 200.49 | 303.7 | 342.3 |
Total Liabilities & Equity | 535.54 | 688.14 | 669.34 | 355.6 | 416.76 | 476.77 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Total Debt | 58.14 | 55.73 | 28.3 | 30.61 | 11.96 | 13.04 |
Net Cash (Debt) | 385.39 | 537.21 | 581.28 | 257.29 | 297.18 | 282.68 |
Net Cash Growth | -11.17% | -7.58% | 125.92% | -13.42% | 5.13% | 0.55% |
Net Cash Per Share | 3.85 | 6.20 | 8.66 | 4.74 | 6.11 | 6.59 |
Book Value | 402.63 | 538.75 | 526.99 | 200.49 | 303.7 | 342.3 |
Book Value Per Share | 4.02 | 6.22 | 7.85 | 3.69 | 6.25 | 7.98 |
Tangible Book Value | 402.63 | 538.75 | 526.99 | 200.49 | 303.7 | 342.3 |
Tangible Book Value Per Share | 4.02 | 6.22 | 7.85 | 3.69 | 6.25 | 7.98 |